New Antibacterials Against D,D- and L,D-Transpeptidases

Case ID:
Disclosure Date:
Unmet need
b-lactam antibacterial agents target peptidoglycan biosynthesis and are used for treatment of infection, but have been ineffective in treatment of Tuberculosis (TB). This lack of activity has been attributed to the presence of b-lactamase and limited penetration of the thick mycolate coat. Thus, new generation of antibacterial agents to treat TB, a disease that causes more deaths worldwide than any other infectious disease, are urgently needed.

Technology overview
Johns Hopkins researchers have identified novel b-lactam antibacterials that contain a bicyclic penem core. The current antibacterials are poor substrates for β-lactamases, and can also inhibit non-classical transpeptidases, l,d-transpeptidases, that generate the majority of linkages in the peptidoglycan of mycobacteria. They verified that these compounds bind l,d-transpeptidases of several bacterial pathogens, using kinetics and x-ray structural studies. The pathogens include Gram-positive, Gram-negative and acid-fast bacteria.
Stage of development
Kumar P et al. Nat Chem Biol 13(1), 54–61, 2017
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
ANTIBACTERIAL AGENTS AGAINST D,D- AND L,D-TRANSPEPTIDASES PCT: Patent Cooperation Treaty United States 16/340,244 4/8/2019     Pending
For Information, Contact:
Christine Joseph
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum